Industry News

Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment

04/05/2021

Excerpt from the Press Release: SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) — Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute. Despite the relative “ease” of surgical resection of such tumors, there lies significant risk in the recurrence of…

Read More

CureVac’s COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant

04/02/2021

Excerpt from the Press Release: The preclinical study found CureVac’s candidate, dubbed CVnCoV, protected mice against COVID-19 in a virus challenge study with the B.1.351 variant of the SARS-CoV-2 virus. The variant, first identified in South Africa, bears certain mutations that make it more contagious than the original virus. It marks the first mouse challenge…

Read More

Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells For Difficult-To-Treat Tumors

04/01/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ — Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, today announced several important steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates. ExaNK™ cells are generated from induced pluripotent stem cells (iPSCs) that are made using mRNA-based cell-reprogramming and gene-editing…

Read More

Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

03/31/2021

Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately…

Read More

Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

03/30/2021

Excerpt from the Article: Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response. If approved, it holds the potential of…

Read More

Radiologists Spot Chest X-ray Abnormalities Better with Deep-Learning Detection

03/29/2021

Excerpt from the Article: Simultaneous use of a deep-learning based detection (DLD) system improves a radiologist’s accuracy in identifying major abnormalities on chest X-rays, a new study has found. While the efficacy of artificial intelligence (AI) algorithms as a second reader has been well established in previous studies, providers included in those investigations have read…

Read More

Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

03/29/2021

Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for…

Read More

AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis

03/26/2021

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had…

Read More

SeaSpine Announces Agreement to Acquire 7D Surgical

03/25/2021

Excerpt from the Press Release: CARLSBAD, Calif., March 22, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has entered into an agreement to acquire all of the issued and outstanding shares of 7D Surgical, Inc.,…

Read More

BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19

03/25/2021

Excerpt from the Press Release: PARIS and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) — BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients…

Read More